Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Forns

Showing results (261-270 of 298) with videos related to

Pageof 30
Sort By:
Gastroenterologia Y Hepatologia|February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Journal of Hepatology|January 27, 2019
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodulesZoe Mariño, Anna Darnell, Sabela Lens, et al.
Journal of Hepatology|December 15, 2020
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]Zoe Mariño, Anna Darnell, Sabela Lens, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
Research Square|June 30, 2025
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe diseaseVolker Lohmann, Paul Rothhaar, Christian Heuss, et al.
Revista Espanola De Enfermedades Digestivas|October 29, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Albillos Albillos, María Buti, et al.
Gastroenterologia Y Hepatologia|October 10, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Agustín Albillos, María Buti, et al.
Nature Communications|December 7, 2025
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe diseasePaul Rothhaar, Tomke Arand, Ha Gyu-Thomas Seong, et al.
Pageof 30

Showing results (261-270 of 298) with videos related to

Sort By:
Pageof 30
Gastroenterologia Y Hepatologia|February 2, 2023
mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)Mar Riveiro-Barciela, Luisa Roade, Joan Martínez-Camprecios, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Journal of Hepatology|January 27, 2019
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodulesZoe Mariño, Anna Darnell, Sabela Lens, et al.
Journal of Hepatology|December 15, 2020
Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]Zoe Mariño, Anna Darnell, Sabela Lens, et al.
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
Research Square|June 30, 2025
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe diseaseVolker Lohmann, Paul Rothhaar, Christian Heuss, et al.
Revista Espanola De Enfermedades Digestivas|October 29, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Albillos Albillos, María Buti, et al.
Gastroenterologia Y Hepatologia|October 10, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Agustín Albillos, María Buti, et al.
Nature Communications|December 7, 2025
Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe diseasePaul Rothhaar, Tomke Arand, Ha Gyu-Thomas Seong, et al.
Pageof 30